The American Journal of Medicine
Volume 121, Issue 11, Supplement 2 , Pages S1-S7 , November 2008

Introduction: Chronic Medical Conditions and Depression—the View from Primary Care

  • Richard L. Kravitz, MD, MSPH

      Affiliations

    • Department of Internal Medicine, University of California–Davis, Sacramento, California, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Richard L. Kravitz, MD, MSPH, Department of Internal Medicine, University of California–Davis, 2103 Stockton Boulevard, Grange Building, Suite 2224, Sacramento, California 95817
    • ,
  • Daniel E. Ford, MD, MPH

      Affiliations

    • Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

References 

  1. Family physicians and the primary care physicians workforce in 2004. [Graham Center One-Pager) Am Fam Phys. 2005;71:2260
  2. Bodenheimer T. Primary care—will it survive?. N Engl J Med. 2006;355:861–864
  3. Grumbach K. Primary care in the United States—the best of times, the worst of times. N Engl J Med. 1999;341:2008–2010
  4. Larson EB, Grumbach K, Roberts KB. The future of generalism in medicine. Ann Intern Med. 2005;142:689–690
  5. Green LA, Hames CG, Nutting PA. Potential of practice-based research networks: experiences from ASPN. [Ambulatory Sentinel Practice Network] J Fam Pract. 1994;38:400–406
  6. Hoffman C, Rice D, Sung HY. Persons with chronic conditions: their prevalence and costs. JAMA. 1996;276:1473–1479
  7. Woolf SH, Johnson RE. The break-even point: when medical advances are less important than improving the fidelity with which they are delivered. Ann Fam Med. 2005;3:545–552
  8. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370:851–858
  9. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003;54:216–226
  10. Eaton WW, Armenian H, Gallo J, Pratt L, Ford DE. Depression and risk for onset of type II diabetes: a prospective population-based study. Diabetes Care. 1996;19:1097–1102
  11. Kawakami N, Takatsuka N, Shimizu H, Ishibashi H. Depressive symptoms and occurrence of type 2 diabetes among Japanese men. Diabetes Care. 1999;22:1071–1076
  12. Rugulies R. Depression as a predictor for coronary heart disease: a review and meta-analysis. Am J Prev Med. 2002;23:51–61
  13. Sobel RM, Lotkowski S, Mandel S. Update on depression in neurologic illness: stroke, epilepsy, and multiple sclerosis. Curr Psychiatry Rep. 2005;7:396–403
  14. Moxey E, O'Connor J, Novielli K, Teutsch S, Nash D. Prescription drug use in the elderly: a descriptive analysis. Health Care Financ Rev. 2003;24:127–141
  15. Celexa. [package insert] St. Louis, MO: Forest Pharmaceuticals, Inc; 2007;
  16. Cymbalta. [package insert] Indianapolis, IN: Eli Lilly and Company; 2007;
  17. Effexor XR. [package insert] Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2008;
  18. Fluvoxamine maleate tablets. [package insert] Elizabeth, NJ: Purepac Pharmaceutical Co; 2000;
  19. Lexapro. [package insert] St. Louis, MO: Forest Pharmaceuticals, Inc; 2007;
  20. Prozac. [package insert] Indianapolis, IN: Eli Lilly and Company; 2008;
  21. Paxil. [package insert] Research Triangle Park, NC: GlaxoSmithKline; 2008;
  22. Wellbutrin XL. [package insert] Research Triangle Park, NC: GlaxoSmithKline; 2007;
  23. Zoloft. [package insert] New York, NY: Pfizer Inc; 2008;
  24. Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry. 2007;68(suppl 8):26–34
  25. Davidson KW, Kupfer DJ, Bigger JT, et al. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. Ann Behav Med. 2006;32:121–126
  26. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry. 2003;54:363–375
  27. Williams MM, Clouse RE, Lustman PJ. Treating depression to prevent diabetes: understanding depression as a medical complication. Clin Diabetes. 2006;24:79–86
  28. Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med. 1997;59:241–250
  29. Starkstein SE, Mizrahi R, Power BD. Antidepressant therapy in post-stroke depression. Expert Opin Pharmacother. 2008;9:1291–1298
  30. Sheline YI, Freedland KE, Carney RM. How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease?. Am J Med. 1997;102:54–59
  31. Robinson R, Jorge R, Moser D, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression. JAMA. 2008;299:2391–2400
  32. Lesperance F, Frasure-Smith N, Koszycki D, et al. CREATE Investigators Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297:367–379
  33. Breum L, Bjerre U, Bak JF, Jacobsen S, Astrup A. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism. 1995;44:1570–1576
  34. Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care. 2000;23:618–623
  35. Strik JJ, Honig A, Lousberg R, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med. 2000;62:783–789
  36. Lustman PJ, Clouse RE, Nix BD, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:521–529
  37. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701–709
  38. Lustman PJ, Williams MM, Sayuk GS, Nix BD, Clouse RE. Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care. 2007;30:459–466
  39. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm. 2004;61:160–173quiz 175–176
  40. Jann MW, Slade JH. Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy. 2007;27:1571–1587
  41. Lustman PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE. Cognitive behavior therapy for depression in type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med. 1998;129:613–621
  42. Johnson EM, Whyte E, Mulsant BH, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry. 2006;14:796–802
  43. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders–Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000;
  44. Sayar K, Kirmayer LJ, Taillefer SS. Predictors of somatic symptoms in depressive disorder. Gen Hosp Psychiatry. 2003;25:108–114
  45. Mold JW, Stein HF. The cascade effect in the clinical care of patients. N Engl J Med. 1986;314:512–514
  46. Himelhoch S, Weller WE, Wu AW, Anderson GF, Cooper LA. Chronic medical illness, depression, and use of acute medical services among Medicare beneficiaries. Med Care. 2004;42:512–521
  47. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977;84:191–215
  48. Hays R, Cunningham W, Ettl M, Beck C, Shapiro M. Health-related quality of life in HIV disease. Assessment. 1995;2:363–380
  49. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. Milbank Q. 1996;74:511–544
  50. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, part 2. JAMA. 2002;288:1909–1914
  51. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002;288:1775–1779
  52. Tsai AC, Morton SC, Mangione CM, Keeler EB. A meta-analysis of interventions to improve care for chronic illnesses. Am J Manag Care. 2005;11:478–488
  53. Burt CW, Sisk JE. Which physicians and practices are using electronic medical records?. Health Aff (Millwood). 2005;24:1334–1343
  54. Dorr DA, Wilcox A, Burns L, Brunker CP, Narus SP, Clayton PD. Implementing a multidisease chronic care model in primary care using people and technology. Dis Manag. 2006;9:1–15
  55. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–613
  56. Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr. 2007;12(suppl 13):1–27

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

 Dr. Kravitz is supported by Midcareer Research and Mentoring Award No. K24-MH072756 from the National Institute of Mental Health. Dr. Ford has received grants from the National Institute of Mental Health and the Robert Wood Johnson Foundation for research on the management of depression in primary care.

PII: S0002-9343(08)00862-0

doi: 10.1016/j.amjmed.2008.09.007

The American Journal of Medicine
Volume 121, Issue 11, Supplement 2 , Pages S1-S7 , November 2008

Article Tools